Response to Blier Letter

Response to Blier Letter

[...]the daily doses of escitalopram, while slightly lower for those patients taking it in combination with bupropion (14.0 mg [SD=7.2] for single-blind escitalopram compared with 17.6 mg [SD=4.5] in the monotherapy arm), were not drastically different.

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:The American journal of psychiatry 2012-01, Vol.169 (1), p.95-96
Hauptverfasser: Trivedi, Madhukar H., Rush, A. John, Kurian, Ben T., Nierenberg, Andrew A., Wisniewski, Stephen R., Fava, Maurizio
Format: Artikel
Sprache:eng
Schlagworte:
Antidepressants
Mental depression
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 96
container_issue 1
container_start_page 95
container_title The American journal of psychiatry
container_volume 169
creator Trivedi, Madhukar H.
Rush, A. John
Kurian, Ben T.
Nierenberg, Andrew A.
Wisniewski, Stephen R.
Fava, Maurizio
description [...]the daily doses of escitalopram, while slightly lower for those patients taking it in combination with bupropion (14.0 mg [SD=7.2] for single-blind escitalopram compared with 17.6 mg [SD=4.5] in the monotherapy arm), were not drastically different.
doi_str_mv 10.1176/appi.ajp.2011.11071055r
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_journals_1010504931</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2648504251</sourcerecordid><originalsourceid>FETCH-LOGICAL-a191t-aea9a337d66318ce0e2846034d687ea08921eb730d414ac644a34dee0548b8873</originalsourceid><addsrcrecordid>eNp9kM1LxDAQxYMoWFfv3ix4bp3JR5MedfELCoIoeAvZdha6rNuYdA_-96ZWxJOnYWbee8P8GLtAKBF1deW870u38SUHxDQCjaBUOGAZKqEKzbk5ZBkA8KJW4u2YncS4SS0IzTN2_kzRD7tI-TjkN9ueQt7QOFI4ZUdrt4109lMX7PXu9mX5UDRP94_L66ZwWONYOHK1E0J3VSXQtATEjaxAyK4ymhyYmiOttIBOonRtJaVLOyJQ0qyM0WLBLudcH4aPPcXRboZ92KWTFiF9ArIWmFR6VrVhiDHQ2vrQv7vwmUR2wmAnDDZhsBMG-4shOeXs_Bb8yf7f9gXdG2DH</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1010504931</pqid></control><display><type>article</type><title>Response to Blier Letter</title><source>American Psychiatric Publishing Journals (1997-Present)</source><source>EZB-FREE-00999 freely available EZB journals</source><creator>Trivedi, Madhukar H. ; Rush, A. John ; Kurian, Ben T. ; Nierenberg, Andrew A. ; Wisniewski, Stephen R. ; Fava, Maurizio</creator><creatorcontrib>Trivedi, Madhukar H. ; Rush, A. John ; Kurian, Ben T. ; Nierenberg, Andrew A. ; Wisniewski, Stephen R. ; Fava, Maurizio</creatorcontrib><description>[...]the daily doses of escitalopram, while slightly lower for those patients taking it in combination with bupropion (14.0 mg [SD=7.2] for single-blind escitalopram compared with 17.6 mg [SD=4.5] in the monotherapy arm), were not drastically different.</description><identifier>ISSN: 0002-953X</identifier><identifier>EISSN: 1535-7228</identifier><identifier>DOI: 10.1176/appi.ajp.2011.11071055r</identifier><identifier>CODEN: AJPSAO</identifier><language>eng</language><publisher>Washington: American Psychiatric Publishing</publisher><subject>Antidepressants ; Mental depression</subject><ispartof>The American journal of psychiatry, 2012-01, Vol.169 (1), p.95-96</ispartof><rights>Copyright © American Psychiatric Association 2012</rights><rights>Copyright © American Psychiatric Association</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-a191t-aea9a337d66318ce0e2846034d687ea08921eb730d414ac644a34dee0548b8873</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://psychiatryonline.org/doi/epdf/10.1176/appi.ajp.2011.11071055r$$EPDF$$P50$$Gappi$$H</linktopdf><linktohtml>$$Uhttps://psychiatryonline.org/doi/full/10.1176/appi.ajp.2011.11071055r$$EHTML$$P50$$Gappi$$H</linktohtml><link.rule.ids>314,780,784,2855,21626,21627,21628,27924,27925,77794,77799</link.rule.ids></links><search><creatorcontrib>Trivedi, Madhukar H.</creatorcontrib><creatorcontrib>Rush, A. John</creatorcontrib><creatorcontrib>Kurian, Ben T.</creatorcontrib><creatorcontrib>Nierenberg, Andrew A.</creatorcontrib><creatorcontrib>Wisniewski, Stephen R.</creatorcontrib><creatorcontrib>Fava, Maurizio</creatorcontrib><title>Response to Blier Letter</title><title>The American journal of psychiatry</title><description>[...]the daily doses of escitalopram, while slightly lower for those patients taking it in combination with bupropion (14.0 mg [SD=7.2] for single-blind escitalopram compared with 17.6 mg [SD=4.5] in the monotherapy arm), were not drastically different.</description><subject>Antidepressants</subject><subject>Mental depression</subject><issn>0002-953X</issn><issn>1535-7228</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2012</creationdate><recordtype>article</recordtype><recordid>eNp9kM1LxDAQxYMoWFfv3ix4bp3JR5MedfELCoIoeAvZdha6rNuYdA_-96ZWxJOnYWbee8P8GLtAKBF1deW870u38SUHxDQCjaBUOGAZKqEKzbk5ZBkA8KJW4u2YncS4SS0IzTN2_kzRD7tI-TjkN9ueQt7QOFI4ZUdrt4109lMX7PXu9mX5UDRP94_L66ZwWONYOHK1E0J3VSXQtATEjaxAyK4ymhyYmiOttIBOonRtJaVLOyJQ0qyM0WLBLudcH4aPPcXRboZ92KWTFiF9ArIWmFR6VrVhiDHQ2vrQv7vwmUR2wmAnDDZhsBMG-4shOeXs_Bb8yf7f9gXdG2DH</recordid><startdate>201201</startdate><enddate>201201</enddate><creator>Trivedi, Madhukar H.</creator><creator>Rush, A. John</creator><creator>Kurian, Ben T.</creator><creator>Nierenberg, Andrew A.</creator><creator>Wisniewski, Stephen R.</creator><creator>Fava, Maurizio</creator><general>American Psychiatric Publishing</general><general>American Psychiatric Association</general><scope>AAYXX</scope><scope>CITATION</scope><scope>K9.</scope><scope>NAPCQ</scope></search><sort><creationdate>201201</creationdate><title>Response to Blier Letter</title><author>Trivedi, Madhukar H. ; Rush, A. John ; Kurian, Ben T. ; Nierenberg, Andrew A. ; Wisniewski, Stephen R. ; Fava, Maurizio</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-a191t-aea9a337d66318ce0e2846034d687ea08921eb730d414ac644a34dee0548b8873</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2012</creationdate><topic>Antidepressants</topic><topic>Mental depression</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Trivedi, Madhukar H.</creatorcontrib><creatorcontrib>Rush, A. John</creatorcontrib><creatorcontrib>Kurian, Ben T.</creatorcontrib><creatorcontrib>Nierenberg, Andrew A.</creatorcontrib><creatorcontrib>Wisniewski, Stephen R.</creatorcontrib><creatorcontrib>Fava, Maurizio</creatorcontrib><collection>CrossRef</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Nursing &amp; Allied Health Premium</collection><jtitle>The American journal of psychiatry</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Trivedi, Madhukar H.</au><au>Rush, A. John</au><au>Kurian, Ben T.</au><au>Nierenberg, Andrew A.</au><au>Wisniewski, Stephen R.</au><au>Fava, Maurizio</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Response to Blier Letter</atitle><jtitle>The American journal of psychiatry</jtitle><date>2012-01</date><risdate>2012</risdate><volume>169</volume><issue>1</issue><spage>95</spage><epage>96</epage><pages>95-96</pages><issn>0002-953X</issn><eissn>1535-7228</eissn><coden>AJPSAO</coden><abstract>[...]the daily doses of escitalopram, while slightly lower for those patients taking it in combination with bupropion (14.0 mg [SD=7.2] for single-blind escitalopram compared with 17.6 mg [SD=4.5] in the monotherapy arm), were not drastically different.</abstract><cop>Washington</cop><pub>American Psychiatric Publishing</pub><doi>10.1176/appi.ajp.2011.11071055r</doi><tpages>2</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0002-953X
ispartof The American journal of psychiatry, 2012-01, Vol.169 (1), p.95-96
issn 0002-953X
1535-7228
language eng
recordid cdi_proquest_journals_1010504931
source American Psychiatric Publishing Journals (1997-Present); EZB-FREE-00999 freely available EZB journals
subjects Antidepressants
Mental depression
title Response to Blier Letter
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-27T18%3A14%3A20IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Response%20to%20Blier%20Letter&rft.jtitle=The%20American%20journal%20of%20psychiatry&rft.au=Trivedi,%20Madhukar%20H.&rft.date=2012-01&rft.volume=169&rft.issue=1&rft.spage=95&rft.epage=96&rft.pages=95-96&rft.issn=0002-953X&rft.eissn=1535-7228&rft.coden=AJPSAO&rft_id=info:doi/10.1176/appi.ajp.2011.11071055r&rft_dat=%3Cproquest_cross%3E2648504251%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1010504931&rft_id=info:pmid/&rfr_iscdi=true